BACKGROUND: Cognitive impairment in the form of decreased working memory and executive functions has been recognized as a key deficit in schizophrenia. Neurotropic viruses have been associated with focal gray matter deficits in patients with schizophrenia. We evaluated whether such agents alter cognitive function in schizophrenia. METHODS: The sample consisted of 329 patients diagnosed with schizophrenia or schizoaffective disorder. We evaluated associations between exposure to selected agents (Herpes Simplex Viruses 1 and 2 (HSV1, HSV2 respectively) cytomegalovirus (CMV) and Toxoplasma gondii) and scores on the Trail Making Test (TMT), controlling for relevant variables. RESULTS: Serological evidence of exposure to CMV was associated with impaired performance on TMT part A time to completion (p=0.044), a measure of visual search, working memory, and psychomotor speed. Both CMV and HSV1 were significantly associated with increased errors on TMT part B (p<0.001 for both viruses). HSV2 and T. gondii exposure measures were not associated with any of the cognitive functions evaluated using TMT. CONCLUSIONS: Both CMV and HSV1 are associated with impaired cognitive function in schizophrenia as measured by the TMT. Further analyses to evaluate the impact of other illness related variables including genetic variants are warranted.
BACKGROUND:Cognitive impairment in the form of decreased working memory and executive functions has been recognized as a key deficit in schizophrenia. Neurotropic viruses have been associated with focal gray matter deficits in patients with schizophrenia. We evaluated whether such agents alter cognitive function in schizophrenia. METHODS: The sample consisted of 329 patients diagnosed with schizophrenia or schizoaffective disorder. We evaluated associations between exposure to selected agents (Herpes Simplex Viruses 1 and 2 (HSV1, HSV2 respectively) cytomegalovirus (CMV) and Toxoplasma gondii) and scores on the Trail Making Test (TMT), controlling for relevant variables. RESULTS: Serological evidence of exposure to CMV was associated with impaired performance on TMT part A time to completion (p=0.044), a measure of visual search, working memory, and psychomotor speed. Both CMV and HSV1 were significantly associated with increased errors on TMT part B (p<0.001 for both viruses). HSV2 and T. gondii exposure measures were not associated with any of the cognitive functions evaluated using TMT. CONCLUSIONS: Both CMV and HSV1 are associated with impaired cognitive function in schizophrenia as measured by the TMT. Further analyses to evaluate the impact of other illness related variables including genetic variants are warranted.
Authors: F Markus Leweke; Christoph W Gerth; Dagmar Koethe; Joachim Klosterkötter; Inna Ruslanova; Bogdana Krivogorsky; E Fuller Torrey; Robert H Yolken Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-02 Impact factor: 5.270
Authors: J A Periáñez; M Ríos-Lago; J M Rodríguez-Sánchez; D Adrover-Roig; I Sánchez-Cubillo; B Crespo-Facorro; J I Quemada; F Barceló Journal: Arch Clin Neuropsychol Date: 2007-03-01 Impact factor: 2.813
Authors: Faith B Dickerson; John J Boronow; Cassie Stallings; Andrea E Origoni; Inna Ruslanova; Robert H Yolken Journal: Arch Gen Psychiatry Date: 2003-05
Authors: Joseph H Callicott; Venkata S Mattay; Beth A Verchinski; Stefano Marenco; Michael F Egan; Daniel R Weinberger Journal: Am J Psychiatry Date: 2003-12 Impact factor: 18.112
Authors: Hannu Koponen; Paula Rantakallio; Juha Veijola; Peter Jones; Jari Jokelainen; Matti Isohanni Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-02 Impact factor: 5.270
Authors: Faith B Dickerson; John J Boronow; Cassie Stallings; Andrea E Origoni; Sara Cole; Bogdana Krivogorsky; Robert H Yolken Journal: Biol Psychiatry Date: 2004-03-15 Impact factor: 13.382
Authors: Konasale M Prasad; Shaun M Eack; Dhruman Goradia; Krishna M Pancholi; Matcheri S Keshavan; Robert H Yolken; Vishwajit L Nimgaonkar Journal: Am J Psychiatry Date: 2011-06-01 Impact factor: 18.112
Authors: Vishwajit L Nimgaonkar; Robert H Yolken; Tianxiu Wang; Chung-Chou H Chang; Lora McClain; Eric McDade; Beth E Snitz; Mary Ganguli Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: Michael M Vanyukov; Vishwajit L Nimgaonkar; Levent Kirisci; Galina P Kirillova; Maureen D Reynolds; Konasale Prasad; Ralph E Tarter; Robert H Yolken Journal: Dev Psychopathol Date: 2017-04-19
Authors: Konasale M Prasad; Shaun M Eack; Matcheri S Keshavan; Robert H Yolken; Satish Iyengar; Vishwajit L Nimgaonkar Journal: Schizophr Bull Date: 2012-03-23 Impact factor: 9.306
Authors: Mikhil Bamne; Joel Wood; Kodavali Chowdari; Annie M Watson; Cemil Celik; Hader Mansour; Lambertus Klei; Ruben C Gur; L DiAnne Bradford; Monica E Calkins; Alberto B Santos; Neil Edwards; Joseph Kwentus; Joseph P McEvoy; Trina B Allen; Robert M Savage; Henry A Nasrallah; Raquel E Gur; Rodney T Perry; Rodney C P Go; Bernie Devlin; Robert Yolken; Vishwajit L Nimgaonkar Journal: Schizophr Bull Date: 2012-09-10 Impact factor: 9.306